- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07586111
Effects of Plant Foods on Gastrointestinal and Cardiometabolic Health (PLANTIFUL)
A Randomised Controlled Trial Investigating the Impact of Plant Foods on Gastrointestinal and Cardiometabolic Health
The aim of this randomised controlled trial is to investigate the effects of plant foods on gastrointestinal and cardiometabolic health in healthy adults aged 30-70 years old. The main question it will answer is "what is the effect of plant foods on alpha-diversity of the gut microbiota?".
Researchers will compare two diets containing plant foods to see if they have different effects on gastrointestinal and cardiometabolic health.
Participants will be asked to replace all their meals, snacks and drinks with those provided by the study team for four weeks (6 days/week). Participants will also be asked to attend the research facility on three occasions to:
- Provide a blood sample
- Provide a urine sample
- Provide a stool sample
- Have their body composition assessed
- Have an ultrasound of their artery (arm)
- Have their blood pressure measured
- Answer questionnaires related to dietary intake, mental health, physical activity, quality of life, diet acceptability and adherence
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
London, Yhdistynyt kuningaskunta, SE1 9NH
- Rekrytointi
- King's College London
-
Ottaa yhteyttä:
- Clinical Trial Manager
- Puhelinnumero: +442078484552
- Sähköposti: plantiful@kcl.ac.uk
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Kuvaus
Inclusion Criteria:
- Adults aged 30-70 years of age
- Capacity to give informed consent in English
- Consume equal or less than the average UK plant food intake (number and quantity)
- Consume less than 30 g/d of fibre
- BMI 18.50-29.99 kg/m2
- Willing to complete the trial by adhering to the diet intervention, complete questionnaires, provide stool, urine and blood samples, record weight and other anthropometric values and record food intake throughout the study
- Willing and able to adhere to the protocol for the diet intervention for the whole duration of the trial (e.g., appropriate space in freezer to store meals, access to oven/microwave, no planned travelling)
- Willing to discontinue use of prebiotics and probiotics 4 weeks prior and during the intervention period
- Willing to consume animal products daily
- Medication use is stable in women receiving hormone replacement therapy (stable use for the past 3 months)
Exclusion Criteria:
- Medical history of any of the following: diabetes, major active or historic psychiatric conditions (e.g., schizophrenia), current eating disorder, alcohol abuse, active treatment for cancer in the last year, severe neurological, endocrine, renal, cardiac or pulmonary disease (or any other chronic medical condition), severe oesophagitis, gastritis or duodenitis, active diverticulitis or intestinal/colonic strictures, Coeliac disease, Crohn's disease or Ulcerative colitis, stem cell or organ transplant, gut resection surgery (excluding appendicectomy and cholecystectomy), bleeding disorder, anaphylaxis or any other major or chronic condition known to impact study outcome measures.
- A current diagnosis of IBS, as defined by the Rome IV criteria.
- Taking medications known to affect outcomes of interest, including:
- Prebiotics and probiotics 4 weeks prior to enrolment.
- Antibiotics within 4 weeks of enrolment.
- Medications known to affect blood pressure, appetite, gut motility, glucose control, or lipid levels within 4 weeks of enrolment.
- Taking any dietary supplements, apart from vitamin D or calcium supplements, 4 weeks prior to enrolment.
- Allergy or intolerance to any study food ingredients.
- Unable/dislike/unwilling to consume study foods or adhere to study protocol (e.g., not willing to drink a maximum 9 units of alcohol a week or consume animal products).
- Currently reported pregnant or lactating.
- Unwilling or unable to consume non-halal or non-kosher products.
- Estimated energy requirements of <1,500 kcal/day or >3,000 kcal/day.
- Unexplained or unintentional weight loss in the past six months.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Ennaltaehkäisy
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kolminkertaistaa
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Active Comparator: Study Diet A
Meals, snacks and drinks that contain plant foods provided by the research team for four weeks (6 days a week).
|
Study meals, snacks and drinks will be provided that contain plant foods for four weeks (6 days a week).
Participants will follow guidance in self-selecting foods on one day per week.
Muut nimet:
|
|
Active Comparator: Study Diet B
Meals, snacks and drinks that contain plant foods provided by the research team for four weeks (6 days a week).
|
Study meals, snacks and drinks will be provided that contain plant foods for four weeks (6 days a week).
Participants will follow guidance in self-selecting foods on one day per week.
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Alpha-diversity of the gut microbiota
Aikaikkuna: Week 4
|
The diversity of microbial taxa in faecal samples at 4 weeks assessed by calculating alpha-diversity score from 16S ribosomal RNA sequencing.
|
Week 4
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Absolute and change in alpha-diversity of the gut microbiota
Aikaikkuna: Baseline, Week 4
|
Absolute and change in alpha-diversity as measured by the diversity of micriobial taxa in faecal samples via 16S RNA sequencing.
|
Baseline, Week 4
|
|
Beta-diversity of the gut microbiota
Aikaikkuna: Baseline, Week 4
|
The diversity of microbial taxa in faecal samples by calculating beta-diversity via 16S ribosomal RNA sequencing.
|
Baseline, Week 4
|
|
Microbiota composition
Aikaikkuna: Baseline, Week 4
|
Absolute and change in microbiota composition of faecal samples between baseline and Week 4 as assessed by 16S ribosomal RNA sequencing.
|
Baseline, Week 4
|
|
Targeted faecal and plasma metabolomics
Aikaikkuna: Baseline, Week 4
|
Absolute and change in short-chain fatty acids through Liquid Chromatography - Mass Spectrometry using validated assays.
|
Baseline, Week 4
|
|
Targeted faecal and plasma metabolomics
Aikaikkuna: Baseline, Week 4
|
Absolute and change in bile acids through Liquid Chromatography - Mass Spectrometry using validated assays.
|
Baseline, Week 4
|
|
Untargeted faecal metabolomics
Aikaikkuna: Baseline, Week 4
|
Metabolomics analysis via 1H NMR spectroscopy.
|
Baseline, Week 4
|
|
Faecal water content via oven drying
Aikaikkuna: Baseline, Week 4
|
Absolute and change in water content of faecal samples assessed via oven drying.
|
Baseline, Week 4
|
|
Stool frequency
Aikaikkuna: Baseline, Week 4
|
Absolute and change in stool frequency measured via prospective 7-day stool diary
|
Baseline, Week 4
|
|
Stool consistency
Aikaikkuna: Baseline, Week 4
|
Absolute and change in stool consistency measured by Bristol stool form scale. Scale from 1 to 7.
|
Baseline, Week 4
|
|
Gastrointestinal symptoms
Aikaikkuna: Baseline, Week 4
|
Absolute and change in gastrointestincal symptons measured by Gastrointestinal symptoms rating scale score.
Scored from 15 to 105 with lower scores indicating less severe symptoms.
|
Baseline, Week 4
|
|
Endothelial function
Aikaikkuna: Baseline, Week 4
|
Flow mediated dilation measured via ultrasound of arm.
|
Baseline, Week 4
|
|
Untargeted urine and plasma metabolomics
Aikaikkuna: Baseline, Week 4
|
Metabolomics measured via 1H NMR spectroscopy.
|
Baseline, Week 4
|
|
Targeted plasma and urine metabolomics
Aikaikkuna: Baseline, Week 4
|
Metabolomics via Liquid Chromatography-Mass Spectroscopy using validated assays.
|
Baseline, Week 4
|
|
Blood pressure
Aikaikkuna: Baseline, Week 4
|
Absolute and change in diastolic and systolic blood pressure.
|
Baseline, Week 4
|
|
Body composition
Aikaikkuna: Baseline, Week 4
|
Absolute and change in body composition measured via biolelectrical impedance analysis (BIA).
|
Baseline, Week 4
|
|
Waist circumference
Aikaikkuna: Baseline, Week 4
|
Absolute and change in waist circumference assessed by tape measure.
|
Baseline, Week 4
|
|
Dietary intake
Aikaikkuna: Baseline, Week 4
|
Dietary intake measured by aggregating EPIC Norfolk food frequency questionnaire, daily food and drink diaries and food checklists.
|
Baseline, Week 4
|
|
Biological markers of dietary intake
Aikaikkuna: Baseline, Week 4
|
Absolute and change in biomarkers of dietary intake as measured via validated assays.
|
Baseline, Week 4
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Health-related Quality of Life
Aikaikkuna: Baseline, Week 4
|
Absolute and change in SF-36 questionnaire scores.
|
Baseline, Week 4
|
|
Mental Health
Aikaikkuna: Baseline, Week 4
|
Absolute and change in Patient Health Questionnaire-8 and Anxiety and Depression Scale scores.
|
Baseline, Week 4
|
|
Diet acceptability
Aikaikkuna: Baseline, Week 4
|
Acceptability of diet measured through a diet acceptability questionnaire containing multiple choice and open-ended questions.
|
Baseline, Week 4
|
|
Diet satisfaction
Aikaikkuna: Week 4
|
Absolute diet satisfaction measured by Food benefits assessment scale.
Scored from 41 to 205 with a lower score indicating a higher diet satisfaction.
|
Week 4
|
|
Dietary adherence
Aikaikkuna: Baseline, Week 4
|
Adherence to the intervention as measured by consumption of study meals, snacks and drinks.
|
Baseline, Week 4
|
Yhteistyökumppanit ja tutkijat
Sponsori
Julkaisuja ja hyödyllisiä linkkejä
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muut tutkimustunnusnumerot
- HR-25/26-49752
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .